Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Adult patients with small-cell lung cancer (SCLC) will be treated with nivatrotamab a
monoclonal anti GD2×CD3 bispecific antibody to investigate the safety and tolerability of the
drug.